These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 25800544)

  • 21. Probing the distinct chemosensitivity of Plasmodium vivax liver stage parasites and demonstration of 8-aminoquinoline radical cure activity in vitro.
    Maher SP; Vantaux A; Chaumeau V; Chua ACY; Cooper CA; Andolina C; Péneau J; Rouillier M; Rizopoulos Z; Phal S; Piv E; Vong C; Phen S; Chhin C; Tat B; Ouk S; Doeurk B; Kim S; Suriyakan S; Kittiphanakun P; Awuku NA; Conway AJ; Jiang RHY; Russell B; Bifani P; Campo B; Nosten F; Witkowski B; Kyle DE
    Sci Rep; 2021 Oct; 11(1):19905. PubMed ID: 34620901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites.
    Imwong M; Snounou G; Pukrittayakamee S; Tanomsing N; Kim JR; Nandy A; Guthmann JP; Nosten F; Carlton J; Looareesuwan S; Nair S; Sudimack D; Day NP; Anderson TJ; White NJ
    J Infect Dis; 2007 Apr; 195(7):927-33. PubMed ID: 17330781
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [How much primaquine is needed to eradicate Plasmodium vivax hypnozoites?].
    Muñoz J; Velasco M; Alonso D; Valls ME; Corachán M; Gascón J
    Enferm Infecc Microbiol Clin; 2006 Jan; 24(1):29-30. PubMed ID: 16537060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasmodium vivax Liver and Blood Stages Recruit the Druggable Host Membrane Channel Aquaporin-3.
    Posfai D; Maher SP; Roesch C; Vantaux A; Sylvester K; Péneau J; Popovici J; Kyle DE; Witkowski B; Derbyshire ER
    Cell Chem Biol; 2020 Jun; 27(6):719-727.e5. PubMed ID: 32330444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A recombinant antibody against Plasmodium vivax UIS4 for distinguishing replicating from dormant liver stages.
    Schafer C; Dambrauskas N; Steel RW; Carbonetti S; Chuenchob V; Flannery EL; Vigdorovich V; Oliver BG; Roobsoong W; Maher SP; Kyle D; Sattabongkot J; Kappe SHI; Mikolajczak SA; Sather DN
    Malar J; 2018 Oct; 17(1):370. PubMed ID: 30333026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantifying and preventing Plasmodium vivax recurrences in primaquine-untreated pregnant women: An observational and modeling study in Brazil.
    Corder RM; de Lima ACP; Khoury DS; Docken SS; Davenport MP; Ferreira MU
    PLoS Negl Trop Dis; 2020 Jul; 14(7):e0008526. PubMed ID: 32735631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The
    Gupta DK; Dembele L; Voorberg-van der Wel A; Roma G; Yip A; Chuenchob V; Kangwanrangsan N; Ishino T; Vaughan AM; Kappe SH; Flannery EL; Sattabongkot J; Mikolajczak S; Bifani P; Kocken CH; Diagana TT
    Elife; 2019 May; 8():. PubMed ID: 31094679
    [No Abstract]   [Full Text] [Related]  

  • 28. An Activation-Clearance Model for Plasmodium vivax Malaria.
    Mehra S; McCaw JM; Flegg MB; Taylor PG; Flegg JA
    Bull Math Biol; 2020 Feb; 82(2):32. PubMed ID: 32052192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Killing the hypnozoite--drug discovery approaches to prevent relapse in Plasmodium vivax.
    Campo B; Vandal O; Wesche DL; Burrows JN
    Pathog Glob Health; 2015 May; 109(3):107-22. PubMed ID: 25891812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In Vitro Culture, Drug Sensitivity, and Transcriptome of Plasmodium Vivax Hypnozoites.
    Gural N; Mancio-Silva L; Miller AB; Galstian A; Butty VL; Levine SS; Patrapuvich R; Desai SP; Mikolajczak SA; Kappe SHI; Fleming HE; March S; Sattabongkot J; Bhatia SN
    Cell Host Microbe; 2018 Mar; 23(3):395-406.e4. PubMed ID: 29478773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic and therapeutic pitfalls associated with primaquine-tolerant Plasmodium vivax.
    Spudick JM; Garcia LS; Graham DM; Haake DA
    J Clin Microbiol; 2005 Feb; 43(2):978-81. PubMed ID: 15695723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of combined chloroquine and primaquine treatment in 14 days versus intermittent single dose regimen, in an open, non-randomized, clinical trial, to eliminate Plasmodium vivax in southern Mexico.
    Gonzalez-Ceron L; Rodriguez MH; Sandoval MA; Santillan F; Galindo-Virgen S; Betanzos AF; Rosales AF; Palomeque OL
    Malar J; 2015 Oct; 14():426. PubMed ID: 26518132
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of the hypnozoite: a part of Plasmodium vivax life cycle and survival.
    Hulden L; Hulden L
    Malar J; 2011 Apr; 10():90. PubMed ID: 21496287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Observations on the biological nature of Plasmodium vivax sporozoites.
    Collins WE; Sullivan JS; Morris CL; Galland GG; Richardson BB
    J Parasitol; 1996 Apr; 82(2):216-9. PubMed ID: 8604086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular and immunological analyses of confirmed Plasmodium vivax relapse episodes.
    Maneerattanasak S; Gosi P; Krudsood S; Chimma P; Tongshoob J; Mahakunkijcharoen Y; Sukasem C; Imwong M; Snounou G; Khusmith S
    Malar J; 2017 May; 16(1):228. PubMed ID: 28558712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination.
    Wells TN; Burrows JN; Baird JK
    Trends Parasitol; 2010 Mar; 26(3):145-51. PubMed ID: 20133198
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Control and elimination of Plasmodium vivax.
    Shanks GD
    Adv Parasitol; 2012; 80():301-41. PubMed ID: 23199491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Role of primaquine in malaria control and elimination in French-speaking Africa].
    Briolant S; Pradines B; Basco LK
    Bull Soc Pathol Exot; 2017 Aug; 110(3):198-206. PubMed ID: 28417346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modeling Plasmodium vivax: relapses, treatment, seasonality, and G6PD deficiency.
    Chamchod F; Beier JC
    J Theor Biol; 2013 Jan; 316():25-34. PubMed ID: 22959914
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of a rhesus Plasmodium cynomolgi model to screen for anti-hypnozoite activity of pharmaceutical substances.
    Deye GA; Gettayacamin M; Hansukjariya P; Im-erbsin R; Sattabongkot J; Rothstein Y; Macareo L; Fracisco S; Bennett K; Magill AJ; Ohrt C
    Am J Trop Med Hyg; 2012 Jun; 86(6):931-5. PubMed ID: 22665596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.